What did @abbey.aultman actually say?
In a 129K-view TikTok, @abbey.aultman demonstrated self-administering a blended BPC-157 and TB-500 injection using an insulin needle, placed superficially "on either side of my incision, just as close to my Achilles as possible." She described the technique as "super quick, super easy" and showed her surgical scar. She made no explicit therapeutic claims in this clip, but the hashtag "wolverinestack" and the recovery context carry an implied message: these peptides are accelerating her Achilles healing.
The implied claim is the one worth examining. Subcutaneous peri-incisional injection of a BPC-157/TB-500 blend as a post-surgical Achilles recovery protocol is not a standard-of-care intervention. It is an off-label, largely unproven practice drawn from animal research and bodybuilding subcultures. That context matters.
Does the science back this up?
The honest answer: partially, in animal models, but human clinical trial data is nearly nonexistent. BPC-157 has shown real regenerative signals in rodent tendon research, but no peer-reviewed human RCT has confirmed these effects in Achilles repair.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed extensive rodent data showing BPC-157 accelerates tendon-to-bone healing and upregulates growth hormone receptor expression at injury sites. Separately, Chang et al. (2011, Journal of Applied Physiology) demonstrated BPC-157 improved Achilles tendon healing in rats at the cellular and biomechanical level. These are real findings. They are also rat findings.
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a protein involved in actin regulation and angiogenesis. Goldstein et al. (2012, Annals of the New York Academy of Sciences) documented Tβ4's role in tissue repair and wound healing, including in cardiac and dermal models. Again, robust human RCT data for tendon-specific applications does not yet exist.
What did they get wrong (or right)?
The injection technique shown is consistent with what is described in peptide therapy literature for localized delivery, so she likely got the mechanics right. Superficial subcutaneous injection near the injury site mirrors the approach used in some compounding pharmacy protocols and is anatomically plausible.
What she glossed over is significant, though. Injecting near a surgical incision carries real infection risk, especially self-administered without clinical supervision. She did not mention sterile technique beyond the needle itself. She did not mention that BPC-157 and TB-500 sold for "research purposes" have no guaranteed purity or concentration standards in the U.S., since neither peptide is FDA-approved. Compounded versions from licensed pharmacies operate under different oversight, but that distinction went unaddressed.
The "wolverine stack" framing is where this tips into misleading territory. Attributing near-superhuman healing to a peptide blend is marketing language, not science. It sets expectations the current evidence cannot support.
What should you actually know?
If you are recovering from an Achilles rupture and considering peptide therapy, the evidence base is genuinely intriguing but genuinely incomplete. That is not a reason to dismiss it, but it is a reason to be careful about where you source these compounds and whether a licensed provider is supervising the protocol.
Peri-incisional self-injection without clinical oversight is not low-risk. Post-surgical tissue is vulnerable to infection, and insulin needles used near a healing tendon repair require sterile field discipline that a TikTok tutorial cannot fully convey.
Regulatory status matters here. In the U.S., BPC-157 and TB-500 are not FDA-approved drugs. They are available through compounding pharmacies under prescriber oversight or sold as gray-market "research chemicals" with no quality assurance. Those are not equivalent options. If you are going to explore this, a telehealth provider who can write a prescription to a licensed 503A or 503B compounding pharmacy is meaningfully safer than a research-chemical supplier.
The underlying biology these peptides are targeting, angiogenesis, collagen synthesis, growth factor signaling, is legitimate science. The leap from rat tendon studies to human post-surgical self-injection is where the evidence gets thin.